FY25 consensus $3.31B. The company noted that the reduction in revenue is principally the result of softer than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia at year end and delays in certain purchase orders in the OEM business. Additionally, lower overall order volumes across certain portfolio segments fell short of expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex Announces CEO Transition Amid Strategic Portfolio Shift
- Teleflex names Stuart Randle as interim CEO, succeeding Liam Kelly
- Teleflex price target raised to $135 from $120 at Truist
- Teleflex price target raised to $135 from $120 at RBC Capital
- Teleflex price target raised to $139 from $114 at Wells Fargo